Newsfeeds - Spark Newswire

2 minute read

4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More

Today, 10:51 AM

U.S. crude oil futures traded higher by over 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

EFTR

14 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 10:51 AM

On Wednesday, 216 stocks hit new 52-week lows.

ACOR

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

Today, 10:51 AM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM

1 minute read

News

Invacare Anticipates Annual Pre-Tax Savings Of Approximately $2.8M, With Approximately $1.9MTo Be Realized In 2022

By Benzinga Newsdesk

Today, 10:51 AM

-SEC Filing

IVC

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 10:51 AM

BCDA

13 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 10:51 AM

During Friday's session, 198 companies made new 52-week lows.

ACLX

10 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 10:51 AM

During Thursday, 166 stocks hit new 52-week lows.

ACMR

6 minute read

87 Biggest Movers From Yesterday

By Lisa Levin

Today, 10:51 AM

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit.

ABVC

1 minute read

Invacare Late Yesterday Reported Q4 EPS $0.08 Beats $0.02 Estimate, Sales $226.19M Miss $239.89M Estimate

By Benzinga Newsdesk

Today, 10:51 AM

Invacare (NYSE:IVC) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.02 by 300 percent. This is a 180 percent increase over losses of $(0.10) per share from the same period

IVC